Diabetes

COVID-19 patients with hyperglycemia on hospital admission, with and without diabetes, had increased odds of intubation, ICU admission, and mortality, according to research presented at ENDO 2021.

ENDO 2021: An investigational once-weekly insulin formulation was found as effective as daily basal insulin injection for glucose control with lower rates of hypoglycemia and less weight gain.

Using metabolomic profiling from more than 11 000 individuals, researchers identified common pathways linking seemingly unrelated diseases that often co-occur.

Results from a head-to-head study show the investigational medication, tirzepatide, led to superior A1c and body weight reductions compared to semaglutide.

More than half of adults with obesity who received once-weekly semaglutide lost 15% of body weight, according to the recently published STEP 1 study.

A new modeling study estimates that 64% of US COVID-19 hospitalizations were attributable to at least 1 of 4 pre-existing cardiometabolic conditions.

A new review of >60 000 patients with diabetes found CGM use during the early weeks of the COVID-19 pandemic improved their time in range.

Variability in A1c during the first 2 years after T2D diagnosis is a strong predictor of CV disease; study authors note the risk may be mediated by severe hypoglycemic episodes.

Director of the Brigham and Women's Diabetes Program Marie McDonnell, MD, talked with our editor about 2020 studies on SGLT-2 inhibitors, insulin icodec, and more.

Compared to medication and lifestyle changes, metabolic surgery is more effective in the long-term control of severe T2D, a new study found.

Sotagliflozin reduced CV death and hospitalization for HF in patients with T2D and acute symptomatic HF when given during or immediately after hospitalization.

The most popular features in preventive cardiology this year were interviews with thought leaders on management of diabetes, hypertension, and hypercholesterolemia.

Patients with chronic kidney disease have had no treatment options to slow the certain progression to renal failure. Enter SGLT2 inhibitors. A key clinical trial investigator explains.

Primary care clinicians should be the first to prescribe SGLT2 inhibitors for many reasons, as explained by Prof Jonathan McMurray in this Patient Care interview.

DAPA-CKD investigator Professor John McMurray details the trial and renal and cardiovascular outcomes for Patient Care Online.

Director of the Brigham Diabetes Program at the Brigham and Women's Hospital discusses the latest in diabetes management.

Once-weekly semaglutide 2.0 mg vs 1.0 mg led to statistically significant, superior reductions in A1c and weight in type 2 diabetes patients not at goal, study finds.

Video: Obesity expert Dr Louis Aronne outlines the role of medication in obesity treatment and says primary care is absolutely the place to begin.

Adults with diabetes admitted to a New York City hospital with COVID-19 had a lower mortality risk if they received a statin, a new study found.

Preventive Cardiology Collection Table of Contents: Expert video interviews, short, clinical guideline-focused quizzes, facts at-a-glance slideshows, plus news.

The investigational mineralocorticoid receptor antagonist slowed progression to renal failure by 18% and reduced the composite cardiovascular outcome by 14%, authors report.

According to a new study, adults with T2D who were hospitalized with COVID-19 in northern Italy had a lower mortality rate when treated with sitagliptin.

The association of vascular dementia with T2D is stronger than that of nonvascular or Alzheimer dementia, according to a study presented at EASD.

Empagliflozin is now in FDA fast-track development for prevention of hospitalization for HF and reduced all-cause mortality in patients, with/without diabetes, post-AMI.

A new research article showed that after 1 year of weight loss intervention, 46% of patients with type 2 diabetes achieved remission.

In patients with obesity and type 2 diabetes, metabolic improvements were similar after weight loss induced by surgery or a low-calorie diet.

ADA 2020: A new automatic insulin delivery system improves glycemic control in young people with type 1 diabetes, according to research presented at the American Diabetes Association Virtual Scientific Sessions.

The American Diabetes Association kicks off its Virtual 80th Scientific Sessions on Friday, June 12, 2020. Here is our guide to top sessions.

Diabetes patients are at risk for severe SARS-CoV2 infection. Here, find new evidence-based guidance from an international panel, on how to manage these patients.

FDA has asked 5 US companies to voluntarily recall lots of metformin extended release after detection of NDMA contamination.